mosapride Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1.O=C(O)CC(O)(CC(=O)O)C(=O)O
  • InChIKey: HUZTYZBFZKRPFG-UHFFFAOYSA-N
  • Mol. Mass: 614.02
  • ALogP: 3.09
  • ChEMBL Molecules:
    mosapride citrate  
    mosapride  
More Chemistry

Pharmacology

Alternative names

4-amino-5-chloro-2-ethoxy-n-((4-(4-fluorobenzyl)-2-morpholinyl)methyl)benzamide | as 4370 | as-4370 | benzamide, 4-amino-5-chloro-2-ethoxy-n-((4-((4-fluorophenyl)methyl)-2-morpholinyl)methyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) | gasmotin | mosapride | mosapride citrate | mosapride (citrate) | mosapride citrate dihydrate | mosapride citrate hydrate

Organizations (26)

Research & Development (26)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (16)

Approved Indications (1)


 

Gastritis

Experimental Indications - Clinical Trial Phases 1-4 (16)


 

Colorectal Neoplasms (Phase 4)

Constipation (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Diarrhea (Phase 1)

Dyspepsia (Phase 4)

Endoscopy (Phase 3)

Gastritis (Phase 1)

Gastroesophageal Reflux (Phase 4)

Healthy Volunteers (Phase 4)

Irritable Bowel Syndrome (Phase 4)

Medicine, Chinese Traditional (Phase 1/Phase 2)

Pain (Phase 4)

Postoperative Complications (Phase 4)

Psychological Distress (Phase 4)

Therapeutic Equivalency (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 29
  • # of Trial Organizations: 26

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue